Who is sponsoring NCT04372446?

NCT04372446 is sponsored by Inozyme Pharma.

What condition does NCT04372446 study?

NCT04372446 studies Generalized Arterial Calcification in Infancy, Autosomal Recessive Hypophosphatemic Rickets Type 2.

Is NCT04372446 still recruiting?

NCT04372446 is currently completed. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT04372446

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency

Completed Last updated 1 April 2021

What this trial tests

trial in Generalized Arterial Calcification in Infancy in 38 participants. Completed in 30 September 2020.

Timeline

6 May 2020

Primary endpoint
30 September 2020

30 September 2020

Quick facts

Lead sponsor	Inozyme Pharma
Status	Completed
Study type	OBSERVATIONAL
Enrollment	38
Start date	6 May 2020
Primary completion	30 September 2020
Estimated completion	30 September 2020
Sites	1 location across United States

Conditions studied

Generalized Arterial Calcification in Infancy — all drugs for Generalized Arterial Calcification in Infancy →
Autosomal Recessive Hypophosphatemic Rickets Type 2 — all drugs for Autosomal Recessive Hypophosphatemic Rickets Type 2 →

Sponsor

Inozyme Pharma — full company profile →

Who can join

Eligibility, any sex, with Generalized Arterial Calcification in Infancy or Autosomal Recessive Hypophosphatemic Rickets Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To date, the investigators lack characterization of, the burden of, and the systemic progression of disease in ENPP1 deficiency and ABCC6 deficiency from a patient and/or parent perspective. This study aims to document this characterization, progression as well as the burden of disease. Link to the study registration- https://www.engagehealth.com/survey/TakeSurvey.aspx?SurveyID=8252n62

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lifelong impact of ENPP1 Deficiency and the early onset form of ABCC6 Deficiency from patient or caregiver perspective.
O'Brien C, Khursigara G, Huertas P, Leiro B, et al · · 2022 · cited 3× · PMID 35895733 · DOI 10.1371/journal.pone.0270632

Verify or expand the search:

Other Inozyme Pharma trials

Trials by the same sponsor.

NCT07473973 — ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency · Phase 3 · recruiting
NCT06739980 — The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency · Phase 2 · withdrawn
NCT06283589 — The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Underg · Phase 1 · completed
NCT05734196 — The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency · Phase 1 · recruiting
NCT05050669 — Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04372446 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inozyme Pharma
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04372446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing